08:00 , Mar 17, 1997 |  BC Week In Review  |  Company News

Biorelease, TheraMed Partners Inc. deal

BREL's board terminated the company's planned acquisition of TheraMed (see BioCentury, Oct. 14, 1996). BREL will return the subscriptions of accredited investors who invested in a private financing pending of the merger. The company also...
08:00 , Mar 17, 1997 |  BC Week In Review  |  Company News

Biorelease management update

Hired; Leon Gauci, M.D., Ph.D., as president of Biorelease Technologies; formerly EVP of U.S. operations for Cortecs International Ltd. (DLVRY) Biorelease Corp. (BREL), Bedford, N.H.   Business: Drug delivery  ...
08:00 , Feb 18, 1997 |  BC Week In Review  |  Company News

Biorelease, TheraMed Partners deal

BREL terminated its proposed acquisition of TheraMed Partners , citing cost issues (see BioCentury Oct. 14). BREL also suspended its plan to spin out its Biorelease Technologies Inc. subsidiary, which had held the assets of...
08:00 , Feb 18, 1997 |  BC Week In Review  |  Company News

Biorelease management update

Biorelease Corp. (BREL), Bedford, N.H.   Business: Drug delivery   Promoted: Leon Gauci, M.D., Ph.D., to president; formerly EVP of U.S. operations  ...
07:00 , Oct 14, 1996 |  BC Week In Review  |  Company News

Biorelease deal

BREL announced plans to spin off its blood substitute and drug delivery assets, after which it will engage in a new business of acquiring companies and technology under a new name, Pharmatrage Holdings Inc. In...
07:00 , Sep 19, 1994 |  BC Week In Review  |  Clinical News

Biorelease preclinical data

BREL announced enhanced cell viability and protein production in two mammalian cell lines, at the meeting of the International Society for Artificial Cells, Blood Substitutes and Immobilization Biotechnology in Boston. The agent was tested by...
08:00 , Nov 22, 1993 |  BC Week In Review  |  Company News

Biorelease sales and marketing update

BREL’s Erythrogen cell culture additive posted initial sales of $14,701 in the company’s first quarter ended Sept. 30. The company lost $499,184 (9 cents per share) in the quarter, compared with a loss of $365,952...